AUG 02, 2019 3:20 PM PDT

Can Ecstasy Treat PTSD and Depression?

WRITTEN BY: Annie Lennon

Ecstasy, also known as MDMA or “molly”, is a well-known substance known to induce feelings of euphoria and bliss, followed by a notorious, depressive period known as a come-down. Despite its reputation as a party drug though, in recent years, it has undergone trials for treating mental health disorders including Post Traumatic Stress Disorder (PTSD) and depression. But how effective is it?

Although therapeutic treatments involving ecstasy have been successful in achieving breakthroughs sooner than more conventional methods, some studies have shown that its usage may be linked to depression in a high number of users. A study from 2014 for example showed that past-users of the drug were at a higher risk of clinical levels of depression, impulsiveness, and sleep disturbance than non-users (Taurah: 2014). Another study indicated that teenagers who use ecstasy are more likely than their peers to suffer from elevated depressive symptoms (Montreal University: 2012).

But how? When taken, ecstasy increases the activity of at least three neurotransmitters. Specifically, these are serotonin, norepinephrine and dopamine. The increase in serotonin production is likely responsable for the euphoric experience the substance is known for. However, by releasing large amounts of serotonin in this way, the brain soon becomes depleted of this neurotransmitter, leading to a come-down during the following days. 

Although this comedown is temporary, research on rodents and primates has shown that continual exposure to ecstasy damages serotonin neurotransmitters. For example, primates given ecstasy in moderate to high doses twice daily over four days showed reduced numbers of serotonergic neurons 7 years after the experiment, indicating a potential for long term negative side effects of the substance (NIDA: 2017). 

Despite these cautions, however, it is possible that such negative outcomes may be linked to how the studies were conducted, how dosages were managed, and how participants were guided through their experience. Given legal restructions on conducting academic trials with the drug until recently, for the most part, studies on ecstacsy have been based upon self-reported cases of people taking the drug recreationally, and so do not necessarily reflect its therapeutic potential. 

Although the substance certainly has a risk factor when taken in certain conditions- from taking excessive doses to the substance’s purity being uncontrolled- there is substantial research into how it may be taken safely to prevent negative side effects. Supplements including Alpha Lipoic Acid, Ginger and Vitamin E for example are backed by research to take in conjunction with ecstasy for their neuroprotective properties (Rollesafe.org). 

Dosage and environment also seem to be important to lead to more positive results. Many studies for example have found success in treating PTSD with the substance when in therapeutic settings (Sessa: 2019). Furthermore, results so far seem positive for ecstasy in treating depression, particularly for those who otherwise struggle to share their emotions (White: 2016). 

To conclude, although there are risk factors when taking ecstasy to treat PTSD and depression, these may be mitigated when taken in a clinical, or more therapeutic setting. Alongside this, should supplements be taken to mitigate any potential negative neurological side-effects, the substance seems promising as a tool to help people overcome mental disorders, perhaps even more effectively than traditional therapies and treatments. 

 

Sources

 

Taurah, L. et al: Pub Med 

Montreal University: Science Daily 

NIDA, drugabuse.gov

Rollsafe.org 

Sessa, Ben et al. : Frontiers in Psychiatry 

White, Catriona, BBC

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 03, 2020
Cannabis Sciences
Cannabis Compound Prevents Colon Cancer in Mice
OCT 03, 2020
Cannabis Compound Prevents Colon Cancer in Mice
Second only to skin cancer, colon cancer is the most common cancer diagnosed in both men and women in the US. Now, resea ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 06, 2020
Cannabis Sciences
Cannabis Use May Reduce Cancer Risk by 10%
OCT 06, 2020
Cannabis Use May Reduce Cancer Risk by 10%
A recent meta-analysis of 34 studies found that cannabis use may decrease one’s risk of developing certain kinds o ...
OCT 01, 2020
Drug Discovery & Development
Antidepressants Treats Lazy Eye
OCT 01, 2020
Antidepressants Treats Lazy Eye
A study published in Current Biology revealed how a therapeutic used as an antidepressant and for managing pain could tr ...
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
NOV 26, 2020
Cardiology
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
NOV 26, 2020
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote hear ...
Loading Comments...